February 10th, 2020

Invitation to presentation of Immunovia´s Full Year Report 2019 on February 14, 2020

LUND (Sweden) – Immunovia invites to a teleconference (in English) for investors, analysts and media on Friday, February 14th, 2020 at 8:30 am CET. Immunovia will publish the company’s Full Year 2019 report on February 14th, 2020 at 8:00 am CET.

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period Full Year 2019 Report followed by a Q&A session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:

Dial-in numbers:

Sweden: +46 (0) 8 50 520 424

United States: +1 212 999 6659

Austria: +43 (0) 12530807

Germany: +49 (0) 30 3001 90612

Denmark: +45 3271 4573

Switzerland: +41 (0) 22 592 7103

Spain: +34 91 787 0777

Netherlands: +31 (0) 20 794 8426

Norway: +47 2156 3318

France: +33 (0) 1 7037 7166

United Kingdom (standard international access): +44 (0) 20 3003 2666

Conference code:

(To provide to the operator): Immunovia 

Webcast:

https://channel.royalcast.com/webcast/immunovia/20200214_1/

For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia

Email: julie.silber@immunovia.com

Tel: +46 7 93 486 277

There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

About Immunovia

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###

Download PDF File

Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports